Can reiki ease cancer pain? small study says maybe
NCT ID NCT06354049
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether Reiki, a relaxation therapy where a practitioner places hands on or near the body, could help cancer patients with symptoms like pain and fatigue. Ten adults with cancer who had at least three bothersome symptoms received up to six Reiki sessions. Researchers measured how many people joined and stayed in the study, and how satisfied they were, to see if this approach is worth studying further.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Reiki (a hands-on or hands-above relaxation therapy)
- What this could lead to
- If it works, this could offer a gentle, drug-free way to help cancer patients feel better and manage symptoms like pain and fatigue.
- What could go wrong
- This was a very small, early study with only 10 people, so results may not apply to everyone. It focused on whether the therapy was practical, not on proving it works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
10 people
The number who actually took part.
- Started
-
Aug 2024
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 89 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 - 89. * Neoplasm diagnosis (i.e., ICD-10 C00 - D49) confirmed in electronic health record (EHR)/Caisis * Receiving care at a UH Connor Whole Health Integrative Oncology Clinic. * Reporting at least three ESAS symptoms ≥4/10 at baseline screening including fatigue and ≥2 other symptoms on the 9-item questionnaire. * Able to speak and understand English. * Has an email address, and access to a computer with internet and/or a mobile device with a functioning data plan Exclusion Criteria: * Significant cognitive impairment that has not been corrected. * Significant visual impairment that has not been corrected. * Unable to provide informed consent. * Active psychosis. * Pregnancy. * Metastatic disease. * Reiki therapy within 3 months of study enrollment * Active immunotherapy, chemotherapy, or radiation treatment, or completed within 3 months before study start. Aromatase inhibitors and tamoxifen are exceptions.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Two-Drug combo aims to stall advanced breast cancer
- Can a video game teach cancer patients to tame their pain?
- Blood thinner flush could boost tumor biopsy success